Galera Therapeutics (GRTX) Gets a Buy from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Galera Therapeutics (GRTXResearch Report), with a price target of $10.00. The company’s shares closed yesterday at $1.45.

Selvaraju covers the Healthcare sector, focusing on stocks such as Regulus, Aquestive Therapeutics, and Aeterna Zentaris. According to TipRanks, Selvaraju has an average return of -30.4% and a 23.68% success rate on recommended stocks.

Currently, the analyst consensus on Galera Therapeutics is a Hold with an average price target of $6.00.

See Insiders’ Hot Stocks on TipRanks >>

GRTX market cap is currently $38.89M and has a P/E ratio of -0.55.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.

Read More on GRTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More